JP6742986B2 - 第Ｘａ因子解毒剤の凍結乾燥製剤 - Google Patents

第Ｘａ因子解毒剤の凍結乾燥製剤 Download PDF

Info

Publication number
JP6742986B2
JP6742986B2 JP2017509739A JP2017509739A JP6742986B2 JP 6742986 B2 JP6742986 B2 JP 6742986B2 JP 2017509739 A JP2017509739 A JP 2017509739A JP 2017509739 A JP2017509739 A JP 2017509739A JP 6742986 B2 JP6742986 B2 JP 6742986B2
Authority
JP
Japan
Prior art keywords
seq
mannitol
formulation
arginine
sucrose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017509739A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525704A5 (cg-RX-API-DMAC7.html
JP2017525704A (ja
Inventor
フアン ワン，
フアン ワン，
グレゴリー エー． サチャ，
グレゴリー エー． サチャ，
フォン エム． グエン，
フォン エム． グエン，
Original Assignee
ポートラ ファーマシューティカルズ， インコーポレイテッド
ポートラ ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ポートラ ファーマシューティカルズ， インコーポレイテッド, ポートラ ファーマシューティカルズ， インコーポレイテッド filed Critical ポートラ ファーマシューティカルズ， インコーポレイテッド
Publication of JP2017525704A publication Critical patent/JP2017525704A/ja
Publication of JP2017525704A5 publication Critical patent/JP2017525704A5/ja
Application granted granted Critical
Publication of JP6742986B2 publication Critical patent/JP6742986B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2017509739A 2014-08-20 2015-08-20 第Ｘａ因子解毒剤の凍結乾燥製剤 Active JP6742986B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462039809P 2014-08-20 2014-08-20
US62/039,809 2014-08-20
PCT/US2015/046173 WO2016029061A1 (en) 2014-08-20 2015-08-20 Lyophilized formulations for factor xa antidote

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019165981A Division JP2019206595A (ja) 2014-08-20 2019-09-12 第Ｘａ因子解毒剤の凍結乾燥製剤

Publications (3)

Publication Number Publication Date
JP2017525704A JP2017525704A (ja) 2017-09-07
JP2017525704A5 JP2017525704A5 (cg-RX-API-DMAC7.html) 2018-09-13
JP6742986B2 true JP6742986B2 (ja) 2020-08-19

Family

ID=55351266

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017509739A Active JP6742986B2 (ja) 2014-08-20 2015-08-20 第Ｘａ因子解毒剤の凍結乾燥製剤
JP2019165981A Withdrawn JP2019206595A (ja) 2014-08-20 2019-09-12 第Ｘａ因子解毒剤の凍結乾燥製剤
JP2021172975A Active JP7416549B2 (ja) 2014-08-20 2021-10-22 第Ｘａ因子解毒剤の凍結乾燥製剤
JP2023146769A Pending JP2023158199A (ja) 2014-08-20 2023-09-11 第Ｘａ因子解毒剤の凍結乾燥製剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019165981A Withdrawn JP2019206595A (ja) 2014-08-20 2019-09-12 第Ｘａ因子解毒剤の凍結乾燥製剤
JP2021172975A Active JP7416549B2 (ja) 2014-08-20 2021-10-22 第Ｘａ因子解毒剤の凍結乾燥製剤
JP2023146769A Pending JP2023158199A (ja) 2014-08-20 2023-09-11 第Ｘａ因子解毒剤の凍結乾燥製剤

Country Status (14)

Country Link
US (6) US20160237420A1 (cg-RX-API-DMAC7.html)
EP (2) EP3182993B1 (cg-RX-API-DMAC7.html)
JP (4) JP6742986B2 (cg-RX-API-DMAC7.html)
KR (3) KR102867491B1 (cg-RX-API-DMAC7.html)
CN (2) CN107073082B (cg-RX-API-DMAC7.html)
AU (3) AU2015305413B2 (cg-RX-API-DMAC7.html)
CA (1) CA2961739C (cg-RX-API-DMAC7.html)
DK (1) DK3182993T3 (cg-RX-API-DMAC7.html)
EA (2) EA202091385A3 (cg-RX-API-DMAC7.html)
ES (1) ES2814157T3 (cg-RX-API-DMAC7.html)
IL (2) IL250413B (cg-RX-API-DMAC7.html)
SG (1) SG11201701247RA (cg-RX-API-DMAC7.html)
WO (1) WO2016029061A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201701764B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022003101A (ja) * 2014-08-20 2022-01-11 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子解毒剤の凍結乾燥製剤

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117729A1 (en) * 2009-03-30 2010-10-14 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
US20190046450A1 (en) 2016-02-24 2019-02-14 Portola Pharmaceuticals, Inc. Lyophilized formulations for factor xa antidote
PE20190661A1 (es) 2016-06-17 2019-05-08 Portola Pharm Inc Preparacion de derivados del factor xa
EP3624828B1 (en) * 2017-05-18 2024-08-07 Merck Sharp & Dohme LLC Pharmaceutical formulation comprising incretin-insulin conjugates
US20210196568A1 (en) * 2018-05-21 2021-07-01 Chugai Seiyaku Kabushiki Kaisha Lyophilized formulation sealed in glass container
CN110760479A (zh) * 2019-05-17 2020-02-07 上海交通大学医学院附属瑞金医院 靶向血小板表达的凝血因子Xa及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE177752T1 (de) 1992-12-15 1999-04-15 Corvas Int Inc Neue inhibitoren von faktor xa
CN100553678C (zh) 1999-02-22 2009-10-28 巴克斯特国际有限公司 新的无白蛋白的因子ⅷ制剂
US6586574B1 (en) * 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
ES2254385T3 (es) 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
US6586584B2 (en) * 2001-01-29 2003-07-01 Becton, Dickinson And Company Sequences and methods for detection of Hepatitis C virus
CA2512680A1 (en) * 2003-01-08 2004-07-29 Chiron Corporation Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants
ATE549317T1 (de) 2005-11-08 2012-03-15 Millennium Pharm Inc Pharmazeutische salze und polymorphe aus n-(5- chloro-2-pyridinyl)-2-ää4- ä(dimethylamino)iminomethylübenzoylüaminoü-5- methoxy-benzamid, einem faktor-xa-hemmer
JO3324B1 (ar) * 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
DK2915564T3 (da) * 2007-09-28 2021-02-08 Alexion Pharma Inc Antidoter mod faktor XA-inhibitorer og fremgangsmåder til anvendelse deraf
CN107050437A (zh) 2008-09-03 2017-08-18 奥克塔法马股份有限公司 重组制备的因子viii的新型保护组合物
JP5709316B2 (ja) 2008-11-14 2015-04-30 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子阻害剤のための解毒剤および血液凝固剤と組み合わせて該解毒剤を使用する方法
WO2010117729A1 (en) 2009-03-30 2010-10-14 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
EP2453910B1 (en) 2009-07-15 2016-08-31 Portola Pharmaceuticals, Inc. Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding
US20120121580A1 (en) * 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
US20130165459A1 (en) * 2010-01-12 2013-06-27 Norvartis Pharma Ag Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
KR102049254B1 (ko) * 2010-04-20 2019-11-28 옥타파마 아게 약학 단백질을 위한 신규한 안정화제
US8987285B2 (en) * 2010-12-03 2015-03-24 Portola Pharmaceuticals, Inc. Pharmaceutical compositions, dosage forms and new forms of the compound of formula (I), and methods of use thereof
US9683020B2 (en) * 2011-08-01 2017-06-20 Emory University VLPS containing ligands and methods related thereto
AU2012315516B2 (en) * 2011-09-30 2017-05-04 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
GB201310946D0 (en) * 2013-06-19 2013-07-31 Cambridge Entpr Ltd Antidote
CA2961739C (en) * 2014-08-20 2024-04-30 Portola Pharmaceuticals, Inc. Lyophilized formulations for factor xa antidote

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022003101A (ja) * 2014-08-20 2022-01-11 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子解毒剤の凍結乾燥製剤
JP7416549B2 (ja) 2014-08-20 2024-01-17 ポートラ ファーマシューティカルズ， エルエルシー 第Ｘａ因子解毒剤の凍結乾燥製剤

Also Published As

Publication number Publication date
ZA201701764B (en) 2020-10-28
EP3182993A1 (en) 2017-06-28
ES2814157T3 (es) 2021-03-26
AU2015305413A1 (en) 2017-03-23
AU2015305413B2 (en) 2020-09-24
IL276960A (en) 2020-10-29
JP2023158199A (ja) 2023-10-26
JP7416549B2 (ja) 2024-01-17
US20200299668A1 (en) 2020-09-24
EP3750556A1 (en) 2020-12-16
EA201790415A1 (ru) 2017-08-31
US20210284986A1 (en) 2021-09-16
US11028382B2 (en) 2021-06-08
KR102867491B1 (ko) 2025-10-01
US20160237420A1 (en) 2016-08-18
KR20250150675A (ko) 2025-10-20
EA202091385A3 (ru) 2021-06-30
EA036091B1 (ru) 2020-09-25
EP3182993B1 (en) 2020-07-01
AU2020289768A1 (en) 2021-01-21
JP2022003101A (ja) 2022-01-11
US20250163399A1 (en) 2025-05-22
JP2017525704A (ja) 2017-09-07
KR20230007550A (ko) 2023-01-12
CN113171447B (zh) 2024-05-17
JP2019206595A (ja) 2019-12-05
CN113171447A (zh) 2021-07-27
KR20170042776A (ko) 2017-04-19
EP3182993A4 (en) 2018-01-17
AU2020289768B2 (en) 2024-06-13
KR102482517B1 (ko) 2022-12-28
CN107073082A (zh) 2017-08-18
CN107073082B (zh) 2021-04-30
WO2016029061A1 (en) 2016-02-25
CA2961739C (en) 2024-04-30
US20180320160A1 (en) 2018-11-08
SG11201701247RA (en) 2017-03-30
IL250413B (en) 2020-09-30
IL250413A0 (en) 2017-03-30
EA202091385A2 (ru) 2021-03-31
CA2961739A1 (en) 2016-02-25
US20200299667A1 (en) 2020-09-24
AU2024219698A1 (en) 2024-10-03
DK3182993T3 (da) 2020-09-21
IL276960B (en) 2022-04-01

Similar Documents

Publication Publication Date Title
JP7416549B2 (ja) 第Ｘａ因子解毒剤の凍結乾燥製剤
EP2985033B3 (fr) Composition de facteur vii
US12005144B2 (en) Lyophilized formulations for factor XA antidote
HK40042818A (en) Lyophilized formulations for factor xa antidote
EA048314B1 (ru) Лиофилизированные составы для антидота фактора ха
HK40001910B (en) Lyophilized formulations for factor xa antidote

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200708

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200729

R150 Certificate of patent or registration of utility model

Ref document number: 6742986

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250